Antirreabsortivos ósseos em pacientes odontológicos: noções de conduta para o cirurgião-dentista: uma revisão integrativa/ Bone antiresorptive drugs in dental patients: notions of conduct for dentists: an integrative review

Bruno Araujo Lauande Massete Ribeiro, Danielle Barros de Oliveira, Mayron Guedes Silva, Wandersson Ferreira Saraiva, Paulo Maria Santos Rabelo Júnior, Rosana Costa Casanovas

Abstract


Os antirreabsortivos caracterizam-se por fármacos que atuam inibindo a reabsorção óssea e, em geral, são indicados para tratamento de osteoporose, doença de Paget, prevenção de metástase decorrente de mielomas múltiplos e outros tumores. Entretanto, esses medicamentos têm como efeito colateral a Osteonecrose dos Maxilares Associada a Medicamentos, onde observa-se uma região de osso exposto na maxila ou mandíbula. Objetivou-se analisar a produção científica acerca do assunto e descrever, através de uma revisão integrativa da literatura, as noções de conduta para o cirurgião dentista diante dos efeitos adversos dos antirreabsortivos na cavidade oral. Foi realizada uma busca através das bases de dados PubMed®, MEDLINE®, LILACS® e SciELO® utilizando para a pesquisa os termos “antirreabsortivos”, “osteonecrose”, “Osteonecrose dos Maxilares Associada ao uso de Medicamentos” e “OMAM”, sendo incluídos aqueles que foram artigos publicados em um período ilimitado, em português, inglês e espanhol e disponibilizados na íntegra. Nota-se a necessidade de o cirurgião-dentista fazer um bom diagnóstico das lesões em seus diferentes estágios de desenvolvimentos, além da prevenção da osteonecrose com terapias conservadoras.


Keywords


Osteonecrose, Osteonecrose da Arcada Ósseo Dentária Associada a Bifosfonatos, Assistência odontológica.

References


STARLING, Isabela Rizel Nogueira. TRATAMENTO DE OSTEONECROSE EXTENSA ASSOCIADA AO USO DE ANTI REABSORTIVOS: RELATO DE CASO E REVISÃO DE LITERATURA. Tese (Especialização em Cirurgia e Traumatologia Buco-maxilo-facial) - Faculdade de Odontologia, Universidade Federal de Minas Gerais. Belo Horizonte, p. 53. 2018.

RIBEIRO, Guilherme H.; CHRUN, Emanuely S.; DUTRA, Kamile L.; DANIEL, Filipe I.; GRANDO, Liliane J.. OSTEONECROSIS OF THE JAWS: A REVIEW AND UPDATE IN ETIOLOGY AND TREATMENT. Brazilian Journal Of Otorhinolaryngology, [S.L.], v. 84, n. 1, p. 102-108, jan. 2018a. Elsevier BV. http://dx.doi.org/10.1016/j.bjorl.2017.05.008.

JESUS, Adriele Pereira de; SOUSA FILHO, Francisnei Santos; CARDOSO, Juliana Andrade; CÂNCIO, Antônio Varela; SIMÕES, Cinthia Coelho; FARIAS, Jener Gonçalves de. TRATAMENTO CIRÚRGICO PARA OSTEONECROSE DOS MAXILARES INDUZIDA POR BISFOSFONATOS: RELATOS DE CASOS. Revista da Faculdade de Odontologia - Upf, [S.L.], v. 24, n. 1, p. 22-30, 28 mar. 2019. UPF Editora. http://dx.doi.org/10.5335/rfo.v24i1.8790.

RAMOS, Emilio Andrés; DIAMANTE, Maximiliano; MUIÑO, Juan Manuel; ANTONELLI, Ludmila; GUTIÉRREZ, Josefina; MINIGUTTI, Marcelo; OLIVERA, Brunella; LLEVARÍA, Diego; PUIA, Sebastián Ariel; GUELMAN, Rodolfo; ECHAGUE, Alejo; CARUSO, Diego. PREVENCIÓN DE OSTEONECROSIS ASOCIADA A MEDICAMENTOS Y ENSAYO CLÍNICO MULTICÉNTRICO. Rev. Fac. Odontol. (B.Aires); 34(76): 7-15, 2019

CAMINHA, Raquel D’Aquino Garcia; CHICRALA, Gabriela Moura; SOARES, Luiz Alberto Valente; SANTOS, Paulo Sérgio da Silva. RISK PROFILE FOR ANTIANGIOGENIC AGENT-RELATED OSTEONECROSIS OF THE JAWS. Einstein (São Paulo), [S.L.], v. 17, n. 3, p. 1-9, 2019. Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein. http://dx.doi.org/10.31744/einstein_journal/2019rw4628.

BARIN, Luisa Machado; PILLUSKY, Fernanda Maia; PASINI, Marcela Mozzaquatro; DANESI, Cristiane Cademartori. OSTEONECROSE DOS MAXILARES ASSOCIADA AO USO DE BIFOSFONATOS: UMA REVISÃO DE LITERATURA. Rev. Odontol. Univ. Cid. São Paulo. 28(2): 126-34,mai-ago, 2016.

Vilela-Carvalho LN, Tuany-Duarte N, Andrade-Figueiredo M, LópezOrtega k. OSTEONECROSIS DE LOS MAXILARES RELACIONADOS CON EL USO DE MEDICAMENTOS: DIAGNÓSTICO, TRATAMIENTO Y PREVENCIÓN. Rev. CES Odont. 31(2): 48-63. 2018.

GALVÃO, Letícia Gonçalves; DE MOURA, Rafaella Porto. USO DE BISFOSFONATOS E SUA RELAÇÃO COM A OSTEONECROSE DOS MAXILARES: REVISÃO DE LITERATURA. Tese (Apresentado ao Departamento de Odontologia) - Universidade de Taubaté, p. 33. 2019

CHUENGUE, Eduardo Kailan Unfried; RODRIGUES, Giovana. OSTEONECROSE DOS MAXILARES EM PACIENTES TRATADOS COM BISFOSFONATOS: UMA PATOLOGIA SECUNDÁRIA Rev. Saberes, Rolim de Moura, vol. 8, n. 2, jul./set, 2018. ISSN: 2358-0909.

LUCIANO, Daniella Mayra Azevedo; DOMINGUETE, Matheus Henrique Lopes. OSTEONECROSE DOS OSSOS MAXILARES POR USO DE BIFOSFONATO. Rev da Universidade Vale do Rio Verde | v. 16 | n. 1 | jan./jul. 2018 | p. 1

SHIBAHARA T: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): A twist of fate in the bone. Tohoku J Exp Med. 2019, 247:75-86.

Migliorati CA, Brennan MT, Peterson DE. Medication-Related Osteonecrosis of the Jaws. J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53)

Richardson ED, Price DK, Figg WD. Significant addition to treatment options for bone metastasis in prostate cancer. Cancer Biol Ther. 2012;13(2):69–70.

Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E: Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment?. Oral Dis. 2018, 24:238-42.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014, 72:1938-56.

Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S: Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016, 2016:8768162.

Khan AA, Morrison A, Kendler DL, et al.: Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom. 2017, 20:8-24

Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer. 2010;46(2):420–429.

Carvalho A, Mendes RA, Carvalho DCJ. Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos. Acta Med Port 2008 21(5):505-10.

Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009 Feb;122(2 Suppl):S33-45.

FEDE, Olga di; PANZARELLA, Vera; MAUCERI, Rodolfo; FUSCO, Vittorio; BEDOGNI, Alberto; LOMUZIO, Lorenzo; BOARD, Sipmo Onj; CAMPISI, Giuseppina. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: new paradigm of primary prevention. Biomed Research International, [S.L.], v. 2018, p. 1-10, 16 set. 2018.

NICOLATOU-GALITIS, Ourania; SCHIØDT, Morten; MENDES, Rui Amaral; RIPAMONTI, Carla; HOPE, Sally; DRUDGE-COATES, Lawrence; NIEPEL, Daniela; WYNGAERT, Tim van Den. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology And Oral Radiology, [S.L.], v. 127, n. 2, p. 117-135, fev. 2019.

Dal Prá KJ, Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg. 2017 Feb;46(2):151-156.

Marx RE, Cillo JE Jr, Ulloa. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397- 410.

Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of Cterminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(6):1167-73.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3-23.

RAMAGLIA, Luca et al. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clinical oral investigations, v. 22, n. 2, p. 597-615, 2018.

Scarpa LC, Leite LCM, Lacerda JCT, Arantes DCB. Osteonecrose nos ossos da maxila e mandíbula associada ao uso do bifosfonato de sódio. Rev Bras Pesqui Saude 2010 12(1):86-92.

Silva AS, Conceição TS, Veloso KMM, Cartágenes MSS. Análise de prontuários de pacientes com câncer de mama em tratamento com bisfosfonatos: fator de risco para manifestações orais e osteonecrose induzida. Rev Soc Bras Clín Méd 2013 jul-set;11(3):242-5.

Santos PSS, Gambirazi LM, Felix VB, Magalhães MHCG. Osteonecrose maxilar em pacientes portadores de doenças neoplásicas sob uso de bisfosfonatos. Rev Bras Hematol Hemoter 2008 dez;30(6):501-4.

Ferreira Junior CD, Casado PL, Barboza ESP. Osteonecrose associada aos bifosfonatos na odontologia. Rev Periodontia 2007 dez;17(24-30):4.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005 Dec 1;23(34):8580-7.

Gomez-Moreno G, Arribas-Fernandez MC, Fernandez-Guerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment. Eur Rev Med Pharmacol Sci 2014 18(9):1391-7.

RUGANI, P., ACHAM, S., KIRNBAUER, B., TRUSCHNEGG, A., OBERMAYER-PIETSCH, B., & Jakse, N. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series. Clinical oral investigations, 19(6), 1329–1338. (2015).

CANO-DURÁN, Jorge A. et al. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). Journal of clinical and experimental dentistry, v. 9, n. 8, p. e1051, 2017.

PINTO, Nelson R. et al. Leucocyte-and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets, v. 29, n. 5, p. 468-475, 2018.

NØRHOLT, S. E.; HARTLEV, J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. International journal of oral and maxillofacial surgery, v. 45, n. 10, p. 1256-1260, 2016.

KIM, Jin-Woo; KIM, Sun-Jong; KIM, Myung-Rae. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. British journal of oral and maxillofacial surgery, v. 52, n. 9, p. 854-859, 2014.

MALUF, Gustavo; CALDAS, Rogério Jardim; SANTOS, Paulo Sérgio Silva. Use of leukocyte-and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, v. 76, n. 1, p. 88-96, 2018.

TENORE, Gianluca et al. Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte-and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. Journal of Clinical Medicine, v. 9, n. 11, p. 3505, 2020.

MINAMISAKO, M. C. et al. Medication-related osteonecrosis of jaws: A low-level laser therapy and antimicrobial photodynamic therapy case approach. Case Rep Dent, v. 2016, 6267406, 2016. doi: 10.1155/2016/6267406.

MENEZES, I. L. et al. Photodynamic therapy in the treatment of mandibular osteonecrosis by bisphosphonates: a review. Brazilian Journal of Health Review, Curitiba, v.4, n.1, p 2652-2665 jan./feb. 2021

SOUZA, Smyrna Luiza Ximenes de et al. Photodynamic therapy as a coadjuvant in the treatment of medication-related osteonecrosis of the jaw (MRONJ) SALUSVITA, Bauru, v. 38, n. 4, p. 1093-1105, 2019.

PRAZMO, E. J.; KWASNY, M.; LAPINSKI, A. M. Photodynamic therapy as a promising method used in the treatment of oral diseases. Adv Clin Exp Med, Wroclaw, v. 25, n. 4, p. 799-807, 2016.

RIBEIRO, G. H. et al. Osteoradionecrosis of the jaws: case series treated with adjuvant low-level laser therapy and antimicrobial photodynamic therapy. J Appl Oral Sci, v. 26, p. e20170172, 2018b. doi: 10.1590/1678-7757-2017-0172.

Freiberger JJ, Padilla-Burgos R, McGraw T, et al: What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 70:1573, 2012.

Freiberger JJ: Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:96, 2009.

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Sep 1;37(25):2270-2290.




DOI: https://doi.org/10.34119/bjhrv4n2-387

Refbacks

  • There are currently no refbacks.